Last reviewed · How we verify
ISCOMATRIX™
At a glance
| Generic name | ISCOMATRIX™ |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of a Dengue Vaccine (V180) in Healthy Adults (V180-001) (PHASE1)
- Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002) (PHASE1)
- A Study of V950 in People With Alzheimer Disease (V950-001 AM7) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ISCOMATRIX™ CI brief — competitive landscape report
- ISCOMATRIX™ updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI